Pharmaceutical

Obesity therapies and the multi-indication momentum: how industry is responding

May 24, 2025 - 06:00
Obesity therapies and the multi-indication momentum: how industry is responding

Read the original article

Tags:

Previous Article

NICE endorses CSL Vifor’s sparsentan for IgA nephropathy in adults

Next Article

Medicaid on a spit after Republicans’ budget bill passes House by single vote

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Rollout of Covid vaccines is bumpy, but not unexpected, experts say

Rollout of Covid vaccines is bumpy, but not unexpected,...

Sep 26, 2023

This biotech could one day make human eggs from scratch. But first, they’re trying to rethink IVF

This biotech could one day make human eggs from scratch...

Apr 9, 2023

Opinion: I’m a biopharma supply chain specialist — and even I can’t find the Adderall I’m prescribed

Opinion: I’m a biopharma supply chain specialist — and ...

Apr 15, 2023